Shabir, Kiran, Brown, James E., Afzal, Islam, Gharanei, Seley, Weickert, Martin O., Barber, Thomas M., Kyrou, Ioannis and Randeva, Harpal S. (2021) Asprosin, a novel pleiotropic adipokine implicated in fasting and obesity-related cardio-metabolic disease : comprehensive review of preclinical and clinical evidence. Cytokine & Growth Factor Reviews, 60 . pp. 120-132. doi:10.1016/j.cytogfr.2021.05.002

PDF WRAP-Asprosin-novel-pleiotropic-adipokine-implicated-fasting-obesity-cardio-metabolic-disease-2021.pdf - Accepted Version Embargoed item. Restricted access to Repository staff only until 28 May 2022. Contact author directly, specifying your specific needs. - Requires a PDF viewer. Available under License Creative Commons Attribution Non-commercial No Derivatives 4.0. Download (769Kb)

Request Changes to record.

Abstract

White adipose tissue is a dynamic endocrine organ that releases an array of adipokines, which play a key role in regulating metabolic homeostasis and multiple other physiological processes. An altered adipokine secretion profile from adipose tissue depots frequently characterizes obesity and related cardio-metabolic diseases. Asprosin is a recently discovered adipokine that is released in response to fasting. Following secretion, asprosin acts - via an olfactory G-protein coupled receptor and potentially via other unknown receptor(s) - on hepatocytes and agouti-related peptide-expressing neurons in the central nervous system to stimulate glucose secretion and promote appetite, respectively. A growing body of both in vitro and in vivo studies have shown asprosin to exert a number of effects on different metabolic tissues. Indeed, asprosin can attenuate insulin signalling and promote insulin resistance in skeletal muscle by increasing inflammation and endoplasmic reticulum stress. Interestingly, asprosin may also play a protective role in cardiomyocytes that are exposed to hypoxic conditions. Moreover, clinical studies have reported elevated circulating asprosin levels in obesity, type 2 diabetes and other obesity-related cardio-metabolic diseases, with significant associations to clinically relevant parameters. Understanding the spectrum of the effects of this novel adipokine is essential in order to determine its physiologic role and its significance as a potential therapeutic target and/or a biomarker of cardio-metabolic disease. The present review offers a comprehensive overview of the published literature on asprosin, including both clinical and preclinical studies, focusing on its role in metabolism and cardio-metabolic disease.

Item Type:	Journal Article
Subjects:	Q Science > QP Physiology Q Science > QR Microbiology > QR180 Immunology R Medicine > RC Internal medicine R Medicine > RM Therapeutics. Pharmacology
Divisions:	Faculty of Medicine > Warwick Medical School > Biomedical Sciences Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016) Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Cytokines, Adipose tissues, Fasting -- Health aspects, Obesity -- Risk factors, Non-insulin-dependent diabetes -- Risk factors, Cardiovascular system -- Diseases -- Risk factors
Journal or Publication Title:	Cytokine & Growth Factor Reviews
Publisher:	Elsevier Ltd
ISSN:	1359-6101
Official Date:	August 2021
Dates:	Date Event August 2021 Published 28 May 2021 Available 24 May 2021 Accepted
Volume:	60
Page Range:	pp. 120-132
DOI:	10.1016/j.cytogfr.2021.05.002
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
Related URLs:	Publisher

Request changes or add full text files to a record

Repository staff actions (login required)

View Item